Does Clinical Evidence Support Cannabis for Appetite Increase?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Cannabis has long been associated with increased appetite, but clinical evidence does not support its general use for appetite stimulation in medical care. According to NHS and NICE guidance, cannabis-based medical products are not licensed in the UK for treating poor appetite or weight loss, except in highly specific circumstances (NHS Guidance; NICE NG144).

What The Research Shows

Most research into cannabis and appetite involves either THC (tetrahydrocannabinol) or synthetic cannabinoids such as dronabinol and nabilone. These studies were originally conducted in people with advanced illnesses, including cancer-related cachexia and HIV-associated weight loss, rather than in general populations.

A 2023 review of cannabinoids for appetite stimulation found modest short-term effects, with some participants reporting increased hunger or food enjoyment, but overall results were inconsistent. Few studies demonstrated measurable or sustained weight gain, and most were limited by small sample sizes and short follow-up durations (PubMed Review, 2023).

In older adults or those with dementia, cannabinoids have not been shown to meaningfully improve appetite or nutritional status. NICE dementia guidance notes that appetite loss should be managed through dietary, behavioural, or medical review rather than unlicensed cannabis-based products (NICE NG97). Furthermore, cannabinoids may cause drowsiness, dizziness, or confusion, which could increase the risk of falls and interfere with day-to-day functioning.

What Guidelines Say

NICE and NHS guidance confirm that cannabis-based products may only be prescribed under specialist supervision and only for conditions such as severe epilepsy, chemotherapy-induced nausea, or muscle spasticity in multiple sclerosis. Appetite loss, weight management, and general wellbeing are not recognised clinical indications (NHS Guidance).

The World Health Organization (WHO) also notes that while cannabinoids can influence appetite-regulating pathways, there is no conclusive evidence that they safely or effectively treat appetite loss in clinical practice (WHO: Cannabis and Cannabinoids).

The Clinical Bottom Line

Some trials report short-term increases in appetite from THC or dronabinol.

These effects are inconsistent and rarely linked to significant weight gain.

Older adults may experience confusion or drowsiness from cannabinoids.

NICE, NHS, and WHO do not recommend cannabis for appetite management.

Any use should occur only within formal research settings under specialist supervision.

Any use should occur only within specialist-supervised research settings.

Educational Context: AlleviMed

Educational platforms such as AlleviMed help patients understand how medical cannabis eligibility is assessed in the UK. They explain that appetite stimulation is not a licensed indication, and that prescriptions are restricted to specific, evidence-supported conditions.

Takeaway

Although cannabis can increase appetite in some individuals, clinical evidence does not support its routine use to treat poor appetite or weight loss. NICE, NHS, and WHO agree that cannabis-based products should not be prescribed for this purpose outside regulated research or specialist supervision.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.